Health-e News·25d ago
The rollout of lenacapavir, a treatment for HIV, is being implemented selectively, raising concerns about who benefits from it and who does not. While lenacapavir was expected to significantly impact the epidemic, the limited geographic distribution highlights issues of access and equity, suggesting that the approach may reflect political decisions rather than a comprehensive strategy to end HIV.